NCT04080453 (PLAQSIS) is a clinical trial of Septic shock in Septic Shock, sponsored by University Hospital, Bordeaux.

Who is sponsoring NCT04080453?

NCT04080453 is sponsored by University Hospital, Bordeaux.

What drugs are being tested in NCT04080453?

Interventions in NCT04080453: Septic shock, Systemic Inflammatory Response Syndrome.

What condition does NCT04080453 study?

NCT04080453 studies Septic Shock.

Is NCT04080453 still recruiting?

NCT04080453 is currently completed. Last updated 26 April 2024.

Last reviewed 2024-04-26 · How we verify

NCT04080453: PLAQSIS

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pro-inflammatory Role of Blood Platelets in Critically Ill Patients With Septic Shock.

Completed Last updated 26 April 2024

What this trial tests

trial testing Septic shock in Septic Shock in 202 participants. Completed in 25 April 2024.

Timeline

9 November 2020

Primary endpoint
9 February 2024

25 April 2024

Quick facts

Lead sponsor	University Hospital, Bordeaux
Status	Completed
Study type	OBSERVATIONAL
Enrollment	202
Start date	9 November 2020
Primary completion	9 February 2024
Estimated completion	25 April 2024
Sites	1 location across France

Drugs / interventions tested

Septic shock
Systemic Inflammatory Response Syndrome

Conditions studied

Septic Shock — all drugs for Septic Shock →

Sponsor

University Hospital, Bordeaux

Who can join

18 and older, any sex, with Septic Shock. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Blood platelets play a major role in the inflammatory response. A dysregulation of platelets activation may be one of the contributors to tissue damage in critically ill patients with septic shock. The main objective of this study is to compare platelet activation markers levels (including plasma concentration in CD154, beta thromboglobulin, platelet factor 4, platelet microparticles, soluble CD62, RANTES, GRO-alpha and HMGB-1) at the early phase of a septic shock and a systemic inflammatory response syndrome (SIRS).

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Immunogenic Cell Death, DAMPs and Prothymosin α as a Putative Anticancer Immune Response Biomarker.
Birmpilis AI, Paschalis A, Mourkakis A, Christodoulou P, et al · · 2022 · cited 66× · PMID 35563721 · DOI 10.3390/cells11091415
Dysregulated dendritic cells in sepsis: functional impairment and regulated cell death.
Zheng LY, Duan Y, He PY, Wu MY, et al · · 2024 · cited 23× · PMID 38816685 · DOI 10.1186/s11658-024-00602-9

Verify or expand the search:

Other recruiting trials for Septic Shock

Currently open trials in the same condition.

NCT07179276 — Veno-arterial Carbon Dioxide Partial Pressure Difference (CO2gap) for Early Resuscitation of Septic Shock · NA · recruiting
NCT07383103 — Hydrocortisone and Fludrocortisone for the Treatment of Septic Shock · Phase 4 · recruiting
NCT07419802 — OxiCLEAR (Oxiris Cytokines and Endotoxin Adsorption Rate) Study · recruiting
NCT07264543 — Early Methylene Blue in the Microhemodynamics of Septic Patients · Phase 2, PHASE3 · recruiting
NCT04855786 — External Drainage of Thoracic Duct Lymph to Reduce Inflammatory Cytokines in Septic Shock Patients · NA · recruiting

Other University Hospital, Bordeaux trials

Trials by the same sponsor.

NCT07506928 — NEURO - Prognostication Using Late Somatosensory Evoked - Potentials · NA · not yet recruiting
NCT07524036 — Impact of a Nursing Educational Consultation on the Patient's Adherence to Their Post-stroke Care Plan. · NA · not yet recruiting
NCT07527494 — Digital MEDIcal TWIN for the Prediction of Arrhythmic Sudden Cardiac Death After a Myocardial Infarction · NA · not yet recruiting
NCT07527442 — Efficacy and Safety of Circumcision Alone on Risk of Febrile Urinary Tract Infections in Boys With Posterior Urethral Va · Phase 2 · not yet recruiting
NCT07478523 — FAPI-PET Value for the Initial Screening of Pancreatic and Biliary Cancers · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04080453 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Hospital, Bordeaux
Last refreshed: 26 April 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04080453.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing